$2.48T
Total marketcap
$63.61B
Total volume
BTC 50.22%     ETH 16.05%
Dominance

CymaBay Therapeutics CBAY Stock

32.48 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
3.73B USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

CymaBay Therapeutics Price Chart

CymaBay Therapeutics CBAY Financial and Trading Overview

CymaBay Therapeutics stock price 32.48 USD
Previous Close 8.72 USD
Open 8.54 USD
Bid 0 USD x 1300
Ask 0 USD x 1100
Day's Range 8.35 - 8.75 USD
52 Week Range 1.88 - 11.22 USD
Volume 1.59M USD
Avg. Volume 1.47M USD
Market Cap 820.09M USD
Beta (5Y Monthly) 0.269014
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 14.2 USD

CBAY Valuation Measures

Enterprise Value 708.58M USD
Trailing P/E N/A
Forward P/E -7.377193
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 7.8598127
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -7.479

Trading Information

CymaBay Therapeutics Stock Price History

Beta (5Y Monthly) 0.269014
52-Week Change 326.90%
S&P500 52-Week Change 20.43%
52 Week High 11.22 USD
52 Week Low 1.88 USD
50-Day Moving Average 9.53 USD
200-Day Moving Average 6.57 USD

CBAY Share Statistics

Avg. Volume (3 month) 1.47M USD
Avg. Daily Volume (10-Days) 965K USD
Shares Outstanding 97.51M
Float 86.86M
Short Ratio 7.21
% Held by Insiders 0.31%
% Held by Institutions 74.38%
Shares Short 9.54M
Short % of Float 11.60%
Short % of Shares Outstanding 9.77%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -26.76%
Return on Equity (ttm) -101.15%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -41635000 USD
EBITDA -94744000 USD
Net Income Avi to Common (ttm) -107010000 USD
Diluted EPS (ttm) -1.14
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 236.36M USD
Total Cash Per Share (mrq) 2.42 USD
Total Debt (mrq) 94.63M USD
Total Debt/Equity (mrq) 90.83 USD
Current Ratio (mrq) 5.22
Book Value Per Share (mrq) 1.07

Cash Flow Statement

Operating Cash Flow (ttm) -52287000 USD
Levered Free Cash Flow (ttm) -28473124 USD

Profile of CymaBay Therapeutics

Country United States
State CA
City Newark
Address 7575 Gateway Boulevard
ZIP 94560
Phone 510 293 8800
Website https://www.cymabay.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 60

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Q&A For CymaBay Therapeutics Stock

What is a current CBAY stock price?

CymaBay Therapeutics CBAY stock price today per share is 32.48 USD.

How to purchase CymaBay Therapeutics stock?

You can buy CBAY shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for CymaBay Therapeutics?

The stock symbol or ticker of CymaBay Therapeutics is CBAY.

Which industry does the CymaBay Therapeutics company belong to?

The CymaBay Therapeutics industry is Biotechnology.

How many shares does CymaBay Therapeutics have in circulation?

The max supply of CymaBay Therapeutics shares is 114.79M.

What is CymaBay Therapeutics Price to Earnings Ratio (PE Ratio)?

CymaBay Therapeutics PE Ratio is 0.00000000 now.

What was CymaBay Therapeutics earnings per share over the trailing 12 months (TTM)?

CymaBay Therapeutics EPS is 0 USD over the trailing 12 months.

Which sector does the CymaBay Therapeutics company belong to?

The CymaBay Therapeutics sector is Healthcare.

CymaBay Therapeutics CBAY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16175.09 USD
-1.62
3.94B USD 16125.33 USD 16341.46 USD 3.94B USD
NASDAQ Global Select Market Com NQGS 7876.03 USD
-1.61
7852.08 USD 7955.84 USD
NASDAQ Biotechnology NBI 4195.13 USD
-2.14
4174.1 USD 4266.29 USD
NASDAQ HealthCare IXHC 958.68 USD
-2.07
954.08 USD 972.42 USD
NASDAQ Composite Total Return I XCMP 19659.36 USD
-1.62
19598.88 USD 19861.56 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD